Process for FDA Data Requests To Inform Certain Over-the-Counter Monograph Drug Activities; Procedure
FDA establishes a formal process for issuing data requests to support OTC monograph drug activities, affecting manufacturers and stakeholders in the OTC monograph system.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities involved in OTC monograph drugs should confirm how it applies to their specific situation before acting. There is a time constraint attached: Varies per request; first requests may be issued soon after publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA now has a defined procedure to request data from the public to inform OTC monograph drug activities, including safety, efficacy, and labeling updates.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities involved in OTC monograph drugs
What you must do
Monitor FDA data requests and prepare to submit relevant data within specified deadlines.
Deadline
Varies per request; first requests may be issued soon after publication.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS BILLS-119hr9661ih: Expedited Access to Biosimilars Act
- FDA drafts new ultra-rare disease therapy guidance - European Pharmaceutical Review
- FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List - The National Law Review
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661